The impact of cannabis use disorder and its treatment on opioid-related health consequences: a longitudinal study of VA patients

Active Grant Awarded Last action

Award ID
R01DA064130
Recipient
Awarding agency
Obligated
$1,453,431

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 25% complete
Place of performance
New York, NY 10032, USA

Award details come from USAspending.gov.

Description

Abstract
Over 600,000 people have died from opioid-related overdoses in the united states (U.S.) since 1999, and rates of opioid-related hospitalizations, overdose, and opioid use disorder (OUD) remain high despite policy reforms aimed at reducing their public health burden. Alongside the ongoing opioid crisis, cannabis use has increased significantly, with 40 million adults using cannabis in 2022, 33% of whom will develop cannabis use disorder (CUD). Despite the negative health consequences of CUD, access to its treatment (i.e., non-pharmacologic interventions) remains limited. The ongoing opioid crisis coupled with a dramatic increase in cannabis use in recent decades has prompted research into whether cannabis use contributes to or mitigates opioid-related health risks. Although cannabis use may influence opioid use through various mechanisms, research examining the impact of CUD on opioid-related outcomes remains limited. No longitudinal studies have examined associations between CUD and OUD, opioid-related hospitalizations, and fatal or non-fatal overdoses, and whether receipt of CUD treatment reduces these risks. CUD substantially impacts patients who receive care in the veterans health administration (VHA), one of the largest healthcare systems in the U.S. In the VHA, CUD prevalence has nearly quadrupled since 2005, and opioid-related hospitalizations and overdoses have increased. Our preliminary 2005-2022 data from ∼4.5 million VHA patients show increases in CO-occurring CUD and OUD with an adjusted past-year prevalence of OUD that is markedly higher in patients with CUD (11.36%- 13.19%) than those without (0.72%-1.08%). From 2005-2020, the adjusted annual opioid-related mortality rate per 100,000 persons was also substantially higher in patients with CUD (42.0-180.53) than without CUD (18.9- 33.2 deaths), with a between-group disparity that widened over time. Given these initial results and growing concerns about the health risks of CUD, we propose a cohort study that leverages the size and scope of the VHA electronic health record (EHR) to 1) examine CUD as a risk factor of subsequent opioid-related health outcomes; 2) identify potential barriers and facilitators of non-pharmacologic interventions among patients with CUD and whether receipt of CUD treatment is associated with reduced risk of subsequent opioid-related outcomes, and 3) determine individual and state-level modifiers of these associations. These research aims are complemented by an outstanding interdisciplinary research team with extensive prior collaborations yielding high-impact research, and expertise in veteran health, suds and health services. By identifying CUD as a potential risk factor of opioid-related harms and establishing if engagement in CUD treatment may mitigate these risks, this research has important clinical and public health implications for the ongoing opioid crisis in the U.S. And will provide necessary information to clinicians, healthcare administrators, and policymakers on the opioid- related public health consequences of CUD and its treatment.

Transactions

Action Obligated Date
Amendment $708,556
Amendment $0
Amendment $0
Original award $744,875

Subawards

Subrecipient Amount Awarded
Seattle Institute For Biomedical And Clinical Research Scope of Work at VA Puget Sound Health Care System: To assist with accomplishing these goals, a subaward will be issued to the Seattle Institute for… $101,665
Seattle Institute For Biomedical And Clinical Research Statement of Work Project Description: In this R01 grant proposal, Drs. Ofir Livne and Zach Mannes, Assistant Professors at Columbia University, will aim to… $120,472

Quick answers

Who received award R01DA064130?

R01DA064130 was awarded to The Trustees Of Columbia University In The City Of New York by National Institute on Drug Abuse (National Institutes of Health) on September 12, 2025.

How much is award R01DA064130 worth?

$1,453,431 has been obligated on R01DA064130.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award